Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

NCT05518032 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped prioritization of studies

Conditions

Metastatic Microsatellite Stable Colorectal Carcinoma
Recurrent Colorectal Carcinoma
Stage III Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma

Interventions

PROCEDURE: Biopsy
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Therapeutic Autologous Dendritic Cells

Sponsor

Roswell Park Cancer Institute